Search research articles
Contact Us
Filters
Showing results (11-20 of 21) with videos related to
Page
of 3
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
March 22, 2017
A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours
Maja de Jonge, Vincent A de Weger, Mark A Dickson, et al.
British Journal of Cancer
|
December 27, 2018
A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours
Vincent A de Weger, Maja de Jonge, Marlies H G Langenberg, et al.
British Journal of Cancer
|
May 4, 2021
Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours
Jordi Rodon, Guillem Argilés, Roisin M Connolly, et al.
Lung Cancer (Amsterdam, Netherlands)
|
May 5, 2023
Olaparib and durvalumab in patients with relapsed small cell lung cancer (MEDIOLA): An open-label, multicenter, phase 1/2, basket study
Matthew G Krebs, Jean-Pierre Delord, Thomas R Jeffry Evans, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 1, 2023
First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations
Filip Janku, Tae Min Kim, Gopakumar Iyer, et al.
Neuro-Oncology Advances
|
November 16, 2022
Trotabresib (CC-90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma
Maria Vieito, Matteo Simonelli, Filip de Vos, et al.
Plos One
|
February 27, 2016
Targeted Next Generation Sequencing as a Reliable Diagnostic Assay for the Detection of Somatic Mutations in Tumours Using Minimal DNA Amounts from Formalin Fixed Paraffin Embedded Material
Wendy W J de Leng, Christa G Gadellaa-van Hooijdonk, Françoise A S Barendregt-Smouter, et al.
The Lancet. Oncology
|
October 3, 2024
Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial
Jürgen Wolf, Maximilian Hochmair, Ji-Youn Han, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 8, 2023
Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study
Yvette Drew, Jae-Weon Kim, Richard T Penson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 17, 2025
A phase I dose escalation and cohort expansion study of CB307, a trispecific Humabody® against PSMA, CD137, and albumin in patients with PSMA-positive solid tumors
Johann S de Bono, Anja Williams, Ignacio Melero, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 21) with videos related to
Sort By:
Page
of 3
European Journal of Cancer (Oxford, England : 1990)
|
March 22, 2017
A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours
Maja de Jonge, Vincent A de Weger, Mark A Dickson, et al.
British Journal of Cancer
|
December 27, 2018
A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours
Vincent A de Weger, Maja de Jonge, Marlies H G Langenberg, et al.
British Journal of Cancer
|
May 4, 2021
Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours
Jordi Rodon, Guillem Argilés, Roisin M Connolly, et al.
Lung Cancer (Amsterdam, Netherlands)
|
May 5, 2023
Olaparib and durvalumab in patients with relapsed small cell lung cancer (MEDIOLA): An open-label, multicenter, phase 1/2, basket study
Matthew G Krebs, Jean-Pierre Delord, Thomas R Jeffry Evans, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 1, 2023
First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations
Filip Janku, Tae Min Kim, Gopakumar Iyer, et al.
Neuro-Oncology Advances
|
November 16, 2022
Trotabresib (CC-90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma
Maria Vieito, Matteo Simonelli, Filip de Vos, et al.
Plos One
|
February 27, 2016
Targeted Next Generation Sequencing as a Reliable Diagnostic Assay for the Detection of Somatic Mutations in Tumours Using Minimal DNA Amounts from Formalin Fixed Paraffin Embedded Material
Wendy W J de Leng, Christa G Gadellaa-van Hooijdonk, Françoise A S Barendregt-Smouter, et al.
The Lancet. Oncology
|
October 3, 2024
Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial
Jürgen Wolf, Maximilian Hochmair, Ji-Youn Han, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 8, 2023
Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study
Yvette Drew, Jae-Weon Kim, Richard T Penson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 17, 2025
A phase I dose escalation and cohort expansion study of CB307, a trispecific Humabody® against PSMA, CD137, and albumin in patients with PSMA-positive solid tumors
Johann S de Bono, Anja Williams, Ignacio Melero, et al.
Page
of 3